



Apr 03, 2019

Working

Five things you need to know about PD-1 inhibitor [↗](#)

Alex Brown¹¹BOC Sciences[dx.doi.org/10.17504/protocols.io.zrdf526](https://doi.org/10.17504/protocols.io.zrdf526)

Alex Brown

ABSTRACT

[PD-1 inhibitors](#), including PD-1 antibodies and PD-L1 antibodies, are a new drug for tumor immunotherapy. Unlike surgery, chemoradiotherapy, and targeted drugs, the PD-1 inhibitor itself does not directly kill cancer cells, but rather activates the patient's own immune system to fight cancer.

The first clinical trial of PD-1 inhibitor began in 2006 and it was first officially marketed in September 2014. Since then, it has been selected by *Science* and the American Society of Clinical Oncology as the "Biggest Progress of the Year". The inventor of PD-1 inhibitors has also won the Lasker Award, which is known as the "Nobel Prize in Medicine".

EXTERNAL LINK

<https://medium.com/@yx2017be/five-things-you-need-to-know-about-pd-1-inhibitor-e17ff7ff53e1>



Five things you need to
know about PD-1
inhibitor.docx

PROTOCOL STATUS

Working

We use this protocol in our group and it is working



This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited